U.S., March 26 -- ClinicalTrials.gov registry received information related to the study (NCT06894225) titled 'Proof-of-Concept Study of ACT001 in Adult Patients with Recurrent Glioblastoma Harbouring STAT3-High Signature' on Nov. 27, 2024.
Brief Summary: This trial will study the effectiveness of ACT001 in adult patients whose Glioblastoma have recurred with a STAT3-high signature after standard-of-care treatment with at least radiation therapy.
Study Start Date: April, 2025
Study Type: INTERVENTIONAL
Condition:
Recurrent Glioblastoma
Intervention:
DRUG: ACT001
Patients recruited and have signed informed consent will be initiated on ACT001 400mg twice a day. Treatment course will repeat every 28 days in the absence of disease progre...